WO2012094427A1 - Diagnostic methods - Google Patents
Diagnostic methods Download PDFInfo
- Publication number
- WO2012094427A1 WO2012094427A1 PCT/US2012/020234 US2012020234W WO2012094427A1 WO 2012094427 A1 WO2012094427 A1 WO 2012094427A1 US 2012020234 W US2012020234 W US 2012020234W WO 2012094427 A1 WO2012094427 A1 WO 2012094427A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- assay
- slide
- array
- cells
- fana
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Definitions
- the present invention relates to the field of diagnostic assay systems, and in particular is useful for diagnosing and assessing autoimmune disorders, and more specifically the invention relates to novel methods for performing auto-antibody diagnostic assays.
- Antibodies are proteins produced by the body in response to invading or infectious materials. They constitute one of the many means the body has to protect itself from disease. In normal circumstances, the body can recognize "foreign” from “self tissues, and therefore only generates antibodies to those materials that are “foreign” to the body.
- autoimmune disorders develops when the body begins to produce antibodies to its own tissues.
- the symptoms associated with the onset of an autoimmune disorder can be varied. Also, any of the early symptoms can mimic those of many other diseases.
- ANA anti -nuclear antibody
- the ANA test is a good "first round" screening test to see if somebody has antibody to self tissues.
- FANA fluorescent anti -nuclear antibody assay
- HEp-2 FANA test is a continuous, human epithelial cell line that grows rapidly and readily attaches to solid surfaces such as tissue culture flasks and glass slides.
- the HEp-2 cell also has a large, well defined nucleus.
- the HEp-2 FANA test is made by growing HEp-2 cells on glass slides and fixing the cells permanently on the surface of the slide. The assay is performed by allowing a serum sample from a patient to react to the cells. If anti-nuclear antibodies are present, they will bind to the cells.
- the slides are washed and the antibody is labeled with anti -human Immunoglobulin (Ig) labeled with a fluorescent tag.
- Ig Immunoglobulin
- Auto-antigens used in the ANA test, represent the majority, but not all, of known auto- antigens expressed on the HEp-2 cell. Some auto-antigens found on the HEp-2 cell are not present in the multiplex suspension. Consequently, the multiplex bead method, such as the AtheNA Multi-Lyte ANA Test System (commercially available from Zeus Scientific, Inc., Bridgewater, NJ), contains a bead mix that is built on the Luminex xMAP® platform
- the aforementioned AtheNA Multi-Lyte ANA Test System provides substantially equivalent results, and there are those that feel that the ANA multiplex arrays are adequate and there are those that feel that only the HEp2 cell is sufficient in screening for ANA. However, it is generally agreed that following an acceptable screening method, providing the specific data from a multiplex array would be of extreme value.
- the present invention has been found to achieve substantially similar goals and results without the necessity of using multiplex beads or instrumentation as described therein, by employing, such as by printing, an array of antigen spots in proximity to cells that are fixed on a glass slide or other solid phase, and therefore the present invention is unexpectedly advantageous in that it does not require the involvement of multiplex bead arrays or instrumentation, such as the Luninex instrument referred to in said application.
- Figure 1 shows examples of positive ANA reactions; specific patterns of reactivity are shown using HEp-2 FANA (performed using a conventional slide method).
- Figure 2 shows a dual-spotted slide array for cells utilizing the methods of the present invention.
- Figure 3 shows a slide and flexible grid used to form wells for performing the methods of the present invention.
- Figure 4 shows a formation of wells on a slide useful for performing the methods of the invention, so that each well contains two areas; one with cells and one with a defined antigen array.
- the ANA screening test is widely recognized as a good "first round" screening test to see if a patient has antibody to self tissues, the currently most popular being the fluorescent anti-nuclear antibody assay (FANA), and the currently most popular of the FANA tests being the HEp-2 FANA.
- the assay is performed by allowing the patient serum to react to the cells. If anti-nuclear antibodies are present, they will bind to the cells. The patient antibody is then tagged with anti -human Ig labeled with a fluorescent moiety. When viewed using a properly equipped microscope, specific patterns of reactivity are observed (if present) and some have been highly associated with specific autoimmune disorders.
- the present invention provides novel methods for the substantially simultaneous analysis of autoantigens in a single sample from a subject by combining the known FANA slide tests and multiplex arrays into a single assay, with minimal modifications to each.
- the HEp-2 FANA test comprises a slide test using HEp-2 cells that have been allowed to grow in TC media on the surface of glass slides. The slides are then rinsed and the cells fixed with conventional organic solvents, thus
- This assay can be performed, for example, in the small wells of a microscope slide.
- a multiplex array platform is any platform that enables one to test for multiple analytes simultaneously. Common array systems involve spotting target molecules in precise locations on a solid support such as glass or plastic. A popular example of a widely used multiplex array platform is the system developed and commercially available based on the Luminex® xMAP® Technology (Luminex Corporation, Austin, TX). Other arrays are known to be fabricated with spots, wells, posts, beads, cantilevers, wires, electrodes or fiber optics (see Clinical Chemistry; 56:12 (2010)).
- Reporter Molecule as used herein means the reporter molecule is the fluorescent, visual or chemiluminescent tag that is bound to the detection molecule(s) in the assay.
- the detection molecule may be goat anti-human IgG (for example) that is labeled with phycoerythrin (for example).
- Cellular substrate as used herein means any cellular material or tissue substrate that is generally adhered to a solid support (glass or plastic microscope slide) and then used as part of a biochemical assay for analysis of biomolecules such as antibody or antigens.
- the combination assay as provided by the present invention therefore can be performed without the use of, instrumention such as for example, a conventional Luminex xMAP instrument, which is essentially a flow cytometer that has been modified for use of the Luminex polystyrene microspheres in a multiplex bead assay.
- instrumention such as for example, a conventional Luminex xMAP instrument, which is essentially a flow cytometer that has been modified for use of the Luminex polystyrene microspheres in a multiplex bead assay.
- the present invention is therefore greatly advantageous over know methods in the art for performing similar assays, in the aspect of simplicity and lack of need for expensive instrumentation, among other advantages which will be apparent to those skilled in the art.
- the array in the case of the present invention comprises a series of purified antigens that have been spotted onto a glass slide in proximity to the cellular substrate containing cells that are of interest to analyze.
- the array can be as simple or as complex as desired, depending on the nature of the assay in question. For the ANA example, it is presently preferred that a minimum of 10 highly purified auto-antigens, and preferably a maximum of 20 to 25 highly purified auto-antigens, be used.
- the practice of the methods of the present invention typically begins with a glass slide.
- a glass slide with two "areas" per "well” (see Figure 2 of the drawings) is used.
- the cells of interest are en applied, thereby creating a cellular substrate and fixed into the circular wells in the image shown in Figure 2.
- the purified antigens are spotted in proximity to the substrate as an array in the square wells shown in Figure 2.
- This slide is thereafter packaged and provided to the user of the assay system, for further analysis of patient specimens in accordance with the user's needs.
- the slide may be modified as needed by the user so that wells are formed for each patient specimen.
- the wells can be configured, for example, so that each well contains one circle (HEp2 cells) and one square (purified antigen array).
- Figures 3 and 4 of the drawings depict the formation of these wells.
- This slide can then be used to evaluate patient specimens (for example, serum, urine, plasma, etc.) for reactivity to the combination of the cells and the antigen array, substantially all simultaneously, using suitable reporter molecules well known to those skilled in the art, and thereby providing a novel way to collect the combination of reactivity to naturally occurring biomolecules within fixed cells or tissues, as well as an array of highly specific, highly purified biomolecules.
- the HEp-2 FANA test comprises a slide test using HEp-2 cells that have been allowed to grow in TC media on the surface of the glass slide. They are rinsed and fixed with some organic solvents, which permeabalizes the membrane and keeps them adhered to the glass slide.
- This assay has conventionally been performed in tiny wells of a microscope slide.
- the array in this case according to the invention is a series of purified antigens that have been spotted onto a glass slide for reactivity to the combination of the cells and the antigen array all substantially simultaneously.
- the present invention could be applied to a myriad of other examples including autoimmune, infectious disease, cancer diagnostics, cytological studies, to name only a few. Other examples will be apparent to those skilled in the art. It will also be appreciated that in addition to analysis of serum samples as described above, the methods and teachings of the present invention can be applied to analysis of any biological fluid that may be obtained from a subject; for example, blood, urine, cerebral spinal fluid and plasma, as well as other biological fluids as are well known to those skilled in the art, can all be suitable for obtaining samples upon which to perform the methods of analysis in accordance with the present invention.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201280005699XA CN103460043A (en) | 2011-01-05 | 2012-01-04 | Diagnostic methods |
EP12732021.6A EP2661625A4 (en) | 2011-01-05 | 2012-01-04 | Diagnostic methods |
JP2013548490A JP2014501932A (en) | 2011-01-05 | 2012-01-04 | Diagnosis method |
CA2860690A CA2860690A1 (en) | 2011-01-05 | 2012-01-04 | Diagnostic methods |
AU2012204413A AU2012204413A1 (en) | 2011-01-05 | 2012-01-04 | Diagnostic methods |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161429892P | 2011-01-05 | 2011-01-05 | |
US61/429,892 | 2011-01-05 | ||
US201161524630P | 2011-08-17 | 2011-08-17 | |
US61/524,630 | 2011-08-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012094427A1 true WO2012094427A1 (en) | 2012-07-12 |
Family
ID=46457702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/020234 WO2012094427A1 (en) | 2011-01-05 | 2012-01-04 | Diagnostic methods |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2661625A4 (en) |
JP (1) | JP2014501932A (en) |
CN (1) | CN103460043A (en) |
AU (1) | AU2012204413A1 (en) |
CA (1) | CA2860690A1 (en) |
WO (1) | WO2012094427A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3591402A1 (en) | 2018-07-06 | 2020-01-08 | Euroimmun Medizinische Labordiagnostika AG | Device and method for antibody detection |
EP3591403A1 (en) | 2018-07-06 | 2020-01-08 | Euroimmun Medizinische Labordiagnostika AG | Method for the automated detection of antibodies in a liquid biological sample using an antigen chip |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6939720B2 (en) * | 1995-10-11 | 2005-09-06 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and method |
US20080254482A1 (en) * | 2006-11-22 | 2008-10-16 | Invitrogen Corporation | Autoimmune disease biomarkers |
WO2010030624A1 (en) * | 2008-09-09 | 2010-03-18 | Zeus Scientific, Inc. | Methods for diagnosis and assessment of autoimmune disorders |
US20100285986A1 (en) * | 2007-11-02 | 2010-11-11 | Friedrich Menges | Single-step multiplex immunoassay |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60183559A (en) * | 1984-02-29 | 1985-09-19 | Otsuka Pharmaceut Co Ltd | Method for measuring autoantibody for hepato-cellular membrane antigen |
US5518881A (en) * | 1993-11-02 | 1996-05-21 | Flinders Medical Centre | Transfected cell lines expressing autoantigens and their use in immunoassays for the detection of autoimmune disease |
CN1101936C (en) * | 2000-08-14 | 2003-02-19 | 李永哲 | Preparation method of antinuclear antibody detection reagent Hep-2 cell antigen fragment and its product |
WO2003016575A1 (en) * | 2001-08-17 | 2003-02-27 | Luminex Corporation | Method for characterizing autoimmune disorders |
US20030104439A1 (en) * | 2001-11-30 | 2003-06-05 | Finch Rosalynde J. | Methods of identifying cellular target molecules |
CN2653510Y (en) * | 2003-09-25 | 2004-11-03 | 长沙福滋堂生物技术开发有限公司 | Anti-nuclear antigen detection cell thin sheet |
CN101017168B (en) * | 2007-02-15 | 2012-08-29 | 广州万孚生物技术股份有限公司 | Fluorescence rubber latex quantitative chromatography indicator paper and manufacture method thereof |
US20100267168A1 (en) * | 2007-11-13 | 2010-10-21 | Medipan Gmbh | Method for end titre determination and the evaluation thereof by means of an indirect immunoflurescence assay |
US8630690B2 (en) * | 2009-05-05 | 2014-01-14 | Electric Power Research Institute, Inc. | Thermal contraction compensation for superconducting and cryo-resistive cables |
EP2362222B1 (en) * | 2010-02-22 | 2013-06-26 | Medipan GmbH | Method and device for the simultaneous detection of antibodies bound to synthetic and cellular and/or tissue substrates |
-
2012
- 2012-01-04 WO PCT/US2012/020234 patent/WO2012094427A1/en active Application Filing
- 2012-01-04 CA CA2860690A patent/CA2860690A1/en not_active Abandoned
- 2012-01-04 AU AU2012204413A patent/AU2012204413A1/en not_active Abandoned
- 2012-01-04 CN CN201280005699XA patent/CN103460043A/en active Pending
- 2012-01-04 JP JP2013548490A patent/JP2014501932A/en active Pending
- 2012-01-04 EP EP12732021.6A patent/EP2661625A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6939720B2 (en) * | 1995-10-11 | 2005-09-06 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and method |
US20080254482A1 (en) * | 2006-11-22 | 2008-10-16 | Invitrogen Corporation | Autoimmune disease biomarkers |
US20100285986A1 (en) * | 2007-11-02 | 2010-11-11 | Friedrich Menges | Single-step multiplex immunoassay |
WO2010030624A1 (en) * | 2008-09-09 | 2010-03-18 | Zeus Scientific, Inc. | Methods for diagnosis and assessment of autoimmune disorders |
Non-Patent Citations (1)
Title |
---|
See also references of EP2661625A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3591402A1 (en) | 2018-07-06 | 2020-01-08 | Euroimmun Medizinische Labordiagnostika AG | Device and method for antibody detection |
EP3591406A1 (en) | 2018-07-06 | 2020-01-08 | Euroimmun Medizinische Labordiagnostika AG | Device and method for antibody detection |
EP3591403A1 (en) | 2018-07-06 | 2020-01-08 | Euroimmun Medizinische Labordiagnostika AG | Method for the automated detection of antibodies in a liquid biological sample using an antigen chip |
EP3591401A1 (en) | 2018-07-06 | 2020-01-08 | Euroimmun Medizinische Labordiagnostika AG | Method for the automated detection of antibodies in a liquid biological sample using an antigen chip |
WO2020007597A1 (en) | 2018-07-06 | 2020-01-09 | Euroimmun Medizinische Labordiagnostika Ag | Method for the automated detection of antibodies in a liquid biological sample using an antigen chip and antigen chip therefor |
Also Published As
Publication number | Publication date |
---|---|
CA2860690A1 (en) | 2012-07-12 |
JP2014501932A (en) | 2014-01-23 |
AU2012204413A1 (en) | 2013-08-15 |
EP2661625A1 (en) | 2013-11-13 |
CN103460043A (en) | 2013-12-18 |
EP2661625A4 (en) | 2014-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hartmann et al. | Protein microarrays for diagnostic assays | |
EP1322960B1 (en) | Allergen-microarray assay | |
JP5707421B2 (en) | Method and system for disease diagnosis by simultaneous detection of antibodies bound to synthetic and cell substrates | |
US20080058224A1 (en) | Substrate chemistry for protein immobilization on a rigid support | |
WO2001014425A1 (en) | Multipurpose diagnostic systems using protein chips | |
González-Buitrago et al. | Present and future of the autoimmunity laboratory | |
JP2010500537A (en) | Improved immunoassay containing mutant antigens to reduce non-specific binding | |
EP2661625A1 (en) | Diagnostic methods | |
EP3262422B1 (en) | Antibody detection method and system | |
Bacarese-Hamilton et al. | Allergen microarrays | |
Sauer et al. | Critical role of the sample matrix in a point-of-care protein chip for sepsis | |
US20120040850A1 (en) | Methods for Diagnosis and Assessment of Autoimmune Disorders | |
CA2939789C (en) | Red blood cell detection | |
CA2938935C (en) | Crossmatching blood samples | |
KR20140067104A (en) | Calibration reagent and method | |
US20130217015A1 (en) | Hmga2 as a biomarker for diagnosis and prognosis of ovarian cancer | |
EP3283888B1 (en) | A method for in vitro diagnosis of allergy and related device | |
Saxena et al. | Immunotechnology in Disease Diagnosis | |
WO2008114152A2 (en) | A novel diagnostic sensor for rapid and reproducible ro52 protein domain detection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12732021 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013548490 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012732021 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2012204413 Country of ref document: AU Date of ref document: 20120104 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2860690 Country of ref document: CA |